Posted by Michael Wonder on 18 Jan 2021
HHS regulations with enduring impact on pricing and reimbursement of medical services and technologies
17 January 2021 - The Trump Administration’s grandiose healthcare plans didn’t come to fruition, like the promised repeal and replace of the Affordable Care Act, the pledged overhaul of the prescription drug rebate system, and international price indexing for Medicare Part B (physician-administered) drugs.
Yet, Secretary Azar’s Department of Health and Human Services and Administrator Verma’s Centers for Medicare and Medicaid Services have implemented a number of high-profile regulations that will likely have a lasting impact on the pricing and reimbursement of medical services and technologies.
